Assessing the safety and effects of ATTO-1310 in healthy adults and patients with skin conditions

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus

This study is testing a new drug called ATTO-1310 to see if it's safe and effective for healthy adults and people with skin conditions like atopic dermatitis and chronic itching.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 104 (estimated)
• Ages: 18 Years to 85 Years
• Sex: All
• Sponsor: Attovia Therapeutics Inc (Industry-sponsored)
• Locations: 4 sites (Plainfield, Indiana and 3 other locations)
• Trial ID: NCT06787586 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety, tolerability, and pharmacokinetics of ATTO-1310 in both healthy volunteers and patients suffering from atopic dermatitis and chronic pruritus. The study is structured in four parts, with the first two focusing on healthy adults receiving single and multiple ascending doses of the drug, while the latter two parts involve patients with specific skin conditions receiving a single dose. Participants will be monitored through clinic visits and symptom diaries, and the effects of ATTO-1310 will be compared to a placebo. The trial aims to gather comprehensive data on how the drug behaves in the body and its potential side effects.

Who should consider this trial

Good fit: Ideal candidates include healthy adults aged 18 to 65, as well as adults with a confirmed diagnosis of atopic dermatitis or chronic pruritus.

Not a fit: Patients with significant flares of atopic dermatitis or those outside the specified age and health criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to a new treatment option for patients suffering from atopic dermatitis and chronic pruritus.

How similar studies have performed: While this approach is being tested in this specific context, similar studies have shown promise in evaluating new treatments for atopic dermatitis and chronic pruritus.

Eligibility criteria

Parts 1 \& 2 (Healthy Volunteers) Key Inclusion Criteria:

* Any sex or gender who is 18 to 65 years old
* Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2
* Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs
* Negative pregnancy test for subjects of child-bearing potential
* Use of highly effective forms of birth control

Part 3 (Subjects with Atopic Dermatitis) Inclusion Criteria:

* Any sex or gender who is 18 to 65 years old
* Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2
* Clinically confirmed diagnosis of active AD
* At least a 1-year history of AD and had no significant flares in AD for at least 4 weeks before Screening
* Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1
* EASI score of ≥ 7 at Screening and Day 1
* vIGA-AD score of ≥ 3 at Screening and Day 1
* Use of topical bland emollient (moisturizer) once or twice daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study
* Negative pregnancy test for subjects of child-bearing potential
* Use of highly effective forms of birth control

Part 4 (Subjects with Chronic Pruritus) Inclusion Criteria:

* Any sex or gender who is 18 to 85 years old
* Body weight of 50 to 125 kg, inclusive, and BMI between 18.5 and 40 kg/m2
* Has had chronic pruritus for at least 6 months and is unresponsive to at least a 2-week course of emollient use.
* Chronic pruritus that affects at least 2 of the following body areas: legs, arms, or trunk
* A single PP-NRS score of ≥ 5 in the 24-hour period prior to the Screening visit
* Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1
* Use of a stable dose of topical bland emollient (moisturizer) once or twice daily for at least 2 weeks before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study
* Negative pregnancy test for subjects of child-bearing potential
* Use of highly effective forms of birth control

Parts 1 \& 2 (Healthy Volunteers) Exclusion Criteria:

* Any clinically significant underlying illness.
* History of malignancy within 5 years of Screening, except adequately treated basal carcinoma or in situ carcinoma of the cervix.
* History of major surgery within 8 weeks prior to Day 1
* History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy
* History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV
* Active or latent tuberculosis infection
* Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
* History of drug or alcohol abuse
* Laboratory values outside of the normal range

Exclusion Criteria for Part 3 (Subjects with Atopic Dermatitis):

* Any clinically significant underlying illness
* History of a clearly defined etiology for pruritus other than AD, including but not limited to urticaria, psoriasis, or other non-atopic dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, uncontrolled hyperthyroidism, and infection
* History of malignancy within 5 years of Screening
* History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
* History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy
* History of recurrent eczema herpeticum
* History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months
* History of major depression
* History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
* Active HBV or HCV or is positive for HIV
* Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
* ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening
* History of drug or alcohol abuse
* Subject has applied topical corticosteroid in the 14 days preceding Day 1
* Subject has used prohibited medications or therapies during the specified washout period before Day 1 (as defined in the protocol)
* Laboratory values outside of the normal range

Exclusion Criteria for Part 4 (Subjects with Chronic Pruritus):

* Primary dermatologic diagnosis associated with pruritic skin lesions at the time of screening
* Regional neuropathic disease associated with pruritus
* Severe renal failure requiring dialysis
* Untreated cholestatic liver disease
* Liver function tests (bilirubin, AST, ALT, alkaline phosphatase) \>2.5 times above the upper limit of normal
* History of infectious dermatoses
* Suspected diagnosis of somatoform pruritus
* Suspected diagnosis of drug-induced pruritus
* History of malignancy within 5 years of Screening
* History of unexplained fevers, night sweats, or unintentional weight loss
* Major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
* History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy
* History of known primary immunodeficiency, is considered immunocompromised, untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months
* History of attempted suicide
* History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
* Active HBV or HCV or is positive for HIV.
* Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
* ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening
* History of drug or alcohol abuse
* Use of prohibited medications as defined in the Protocol

Where this trial is running

Plainfield, Indiana and 3 other locations

• Attovia Clinical Site 102 — Plainfield, Indiana, United States (Recruiting)
• Attovia Clinical Site 104 — Saint Joseph, Missouri, United States (Recruiting)
• Attovia Clinical Site 106 — Reno, Nevada, United States (Recruiting)
• Altasciences — Montreal, Quebec, Canada (Active_not_recruiting)

Study contacts

• Principal investigator: Eric Sicard, MD — Altasciences Company Inc.
• Study coordinator: Malinda Longphre, PhD

Conditions Normal Volunteers; Atopic Dermatitis; Atopic Eczema; Chronic Pruritus; Atopic dermatitis; AD; Atopic eczema; Eczema